title: [Antineutrophil cytoplasmic autoantibody positive vasculitis induced by propylthiouracil: a case report].
abstract: OBJECTIVE
  Propylthiouracil (PTU) as a drug used during the treatment of hyperthyroidism could induce antineutrophil cytoplasmic autoantibody-positive vasculitis. Here the author reported a childhood case of antineutrophil cytoplasmic autoantibody-positive vasculitis induced by PTU, which is rarely described.
  
  
  METHODS
  The diagnosis was made according to the symptoms, signs, serum markers and renal biopsy, and the relevant literature was reviewed.
  
  
  RESULTS
  The 12-year-old girl presented with gross hematuria, proteinuria, renal function damage [Ccr 52.46 ml/(min. 1.73 m(2))], positive antineutrophil cytoplasmic autoantibody (ANCA-MPO) (MPO ELISA 140%) and a vasculitis lesion in the renal biopsy sample. She had been treated with PTU for 5 years because of Graves disease. After the diagnosis, the PTU was withdrawn, and prednisone (40 mg/d) and cyclophosphamide (25 mg, Bid) were applied. Three weeks after the therapy with prednisone and cyclophosphamide the gross hematuria disappeared. Three months after the treatment the renal function returned to normal [Ccr 124 mg/(min.1.73 m(2))], and the titer of ANCA-MPO decreased from 140% to 57%.
  
  
  CONCLUSIONS
  PTU may induce antineutrophil cytoplasmic autoantibody positive vasculitis. A right diagnosis and treatment can improve its prognosis of the disease.
authors.affiliation: Department of Pediatric, Peking University First Hospital, Beijing 100034, China.
authors.forename: Jing-jing
authors.initials: JJ
authors.lastname: Zhang
authors.forename: Ying-nan
authors.initials: YN
authors.lastname: Chen
authors.forename: Hui-jie
authors.initials: HJ
authors.lastname: Xiao
authors.forename: Jing-cheng
authors.initials: JC
authors.lastname: Liu
authors.forename: Ji-yun
authors.initials: JY
authors.lastname: Yang
mesh_terms: D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D013956:Antithyroid Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy; D011379:Prognosis; D011441:Propylthiouracil / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D014657:Vasculitis / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D013956:Antithyroid Agents; D011441:Propylthiouracil